Clinical Trial Update: A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and efficacy of MK0859 (Anacetrapib) in Japanese patients with dyslipidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• MK0859 (Anacetrapib) (Anacetrapib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dyslipidemia | Phase 2 | Status: COMPLETED